MedDataX Logo

Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment

NCT ID: NCT01164501

Last Updated: 2014-06-16

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

741 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-07-31

Study Completion Date

2012-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will investigate the efficacy and safety of the BI 10773 in type 2 diabetic patients with renal impairment in order to provide these data for approval for BI 10773 as an antidiabetic agent by regulatory authorities.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus

NCT01370005

Diabetes Mellitus, Type 2 Hypertension
COMPLETED PHASE3

BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

NCT01131676

Diabetes Mellitus, Type 2
COMPLETED PHASE3

Renal Impairment Study of Empagliflozin (BI10773) in Japanese Patients With Type 2 Diabetes

NCT01581658

Diabetes Mellitus, Type 2
COMPLETED PHASE1

Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls

NCT01867307

Diabetes Mellitus, Type 2 Healthy
COMPLETED PHASE2

24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

NCT02182830

Diabetes Mellitus, Type 2 Hypertension
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 2 Renal Insufficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BI 10773 low dose

BI 10773 tablets once daily

Group Type EXPERIMENTAL

BI 10773

Intervention Type DRUG

BI 10773 tablets once daily

Placebo

Intervention Type DRUG

Placebo tablets identical to BI 10773 high dose

BI 10773 high dose

BI 10773 tablets once daily

Group Type EXPERIMENTAL

Placebo

Intervention Type DRUG

Placebo tablets identical to BI 10773 low dose

BI 10773

Intervention Type DRUG

BI 10773 tablets once daily

Placebo

Placebo tablets matching BI 10773

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo tablets identical to BI 10773 high dose

Placebo

Intervention Type DRUG

Placebo tablets identical to BI 10773 low dose

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BI 10773

BI 10773 tablets once daily

Intervention Type DRUG

Placebo

Placebo tablets identical to BI 10773 low dose

Intervention Type DRUG

Placebo

Placebo tablets identical to BI 10773 high dose

Intervention Type DRUG

BI 10773

BI 10773 tablets once daily

Intervention Type DRUG

Placebo

Placebo tablets identical to BI 10773 low dose

Intervention Type DRUG

Placebo

Placebo tablets identical to BI 10773 high dose

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Diagnosis of type 2 diabetes mellitus prior to informed consent and an estimated glomerular filtration rate of \<90 ml/min.
2. Male and female patients on diet and exercise regimen who are pre-treated with any antidiabetic therapy and are on the maximum tolerated dose which has been unchanged for 12 weeks prior to randomisation.
3. HbA1c greater than or equal to 7.0% and less than or equal to 10.0% .
4. Aged 18 years or above.
5. Body Mass Index less than or equal to 45 kg/m2

Exclusion Criteria

1. Uncontrolled hyperglycaemia defined as \>13.3 mmol/L after an overnight fast during placebo run-in.
2. Impaired renal function, defined as an estimated glomerular filtration rate \<15 ml/min.
3. Renal impairment requiring any form of chronic dialysis.
4. Requiring acute dialysis within three months prior to informed consent.
5. Renal transplant recipient.
6. Myocardial infarction, stroke or Transient Ischemic Attack within three months prior to informed consent.
7. Indication of liver disease.
8. Bariatric surgery within the past two years.
9. Medical history of cancer.
10. Blood dyscrasias or any disorders causing hemolysis or unstable red blood cell.
11. Contraindications to pre-existing background antidiabetic therapy.
12. Treatment with anti-obesity drugs.
13. Current treatment with systemic steroids or change in dosage of thyroid hormones within six weeks prior to informed consent or any other uncontrolled endocrine disorder except Type 2 Diabetes.
14. Pre-menopausal women who are nursing or pregnant or are of child-bearing potential and are not practising an acceptable method of birth control.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Eli Lilly and Company

INDUSTRY

Sponsor Role collaborator

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

1245.36.10014 Boehringer Ingelheim Investigational Site

Anaheim, California, United States

Site Status

1245.36.10019 Boehringer Ingelheim Investigational Site

Lomita, California, United States

Site Status

1245.36.10017 Boehringer Ingelheim Investigational Site

Plantation, Florida, United States

Site Status

1245.36.10009 Boehringer Ingelheim Investigational Site

West Palm Beach, Florida, United States

Site Status

1245.36.10018 Boehringer Ingelheim Investigational Site

Honolulu, Hawaii, United States

Site Status

1245.36.10015 Boehringer Ingelheim Investigational Site

Shreveport, Louisiana, United States

Site Status

1245.36.10021 Boehringer Ingelheim Investigational Site

Endwell, New York, United States

Site Status

1245.36.10008 Boehringer Ingelheim Investigational Site

Greenville, North Carolina, United States

Site Status

1245.36.10005 Boehringer Ingelheim Investigational Site

Bethlehem, Pennsylvania, United States

Site Status

1245.36.10003 Boehringer Ingelheim Investigational Site

Melrose Park, Pennsylvania, United States

Site Status

1245.36.10004 Boehringer Ingelheim Investigational Site

Greer, South Carolina, United States

Site Status

1245.36.10012 Boehringer Ingelheim Investigational Site

Corpus Christi, Texas, United States

Site Status

1245.36.10013 Boehringer Ingelheim Investigational Site

Dallas, Texas, United States

Site Status

1245.36.10002 Boehringer Ingelheim Investigational Site

Houston, Texas, United States

Site Status

1245.36.10007 Boehringer Ingelheim Investigational Site

San Antonio, Texas, United States

Site Status

1245.36.10023 Boehringer Ingelheim Investigational Site

Renton, Washington, United States

Site Status

1245.36.10011 Boehringer Ingelheim Investigational Site

Spokane, Washington, United States

Site Status

1245.36.10006 Boehringer Ingelheim Investigational Site

Tacoma, Washington, United States

Site Status

1245.36.20052 Boehringer Ingelheim Investigational Site

Calgary, Alberta, Canada

Site Status

1245.36.20054 Boehringer Ingelheim Investigational Site

Calgary, Alberta, Canada

Site Status

1245.36.20023 Boehringer Ingelheim Investigational Site

Edmonton, Alberta, Canada

Site Status

1245.36.20055 Boehringer Ingelheim Investigational Site

Edmonton, Alberta, Canada

Site Status

1245.36.20048 Boehringer Ingelheim Investigational Site

Winnipeg, Manitoba, Canada

Site Status

1245.36.20051 Boehringer Ingelheim Investigational Site

Mississauga, Ontario, Canada

Site Status

1245.36.20086 Boehringer Ingelheim Investigational Site

Thornhill, Ontario, Canada

Site Status

1245.36.20053 Boehringer Ingelheim Investigational Site

Toronto, Ontario, Canada

Site Status

1245.36.20056 Boehringer Ingelheim Investigational Site

Montreal, Quebec, Canada

Site Status

1245.36.33001 Boehringer Ingelheim Investigational Site

Corbeil-Essonnes, , France

Site Status

1245.36.33042 Boehringer Ingelheim Investigational Site

Nanterre, , France

Site Status

1245.36.33041 Boehringer Ingelheim Investigational Site

Nice, , France

Site Status

1245.36.33036 Boehringer Ingelheim Investigational Site

Paris, , France

Site Status

1245.36.33040 Boehringer Ingelheim Investigational Site

Poitiers, , France

Site Status

1245.36.33037 Boehringer Ingelheim Investigational Site

Reims, , France

Site Status

1245.36.33038 Boehringer Ingelheim Investigational Site

Reims, , France

Site Status

1245.36.33043 Boehringer Ingelheim Investigational Site

Rennes, , France

Site Status

1245.36.33044 Boehringer Ingelheim Investigational Site

Saint-Mandé, , France

Site Status

1245.36.85201 Boehringer Ingelheim Investigational Site

Hong Kong, , Hong Kong

Site Status

1245.36.85204 Boehringer Ingelheim Investigational Site

Hong Kong, , Hong Kong

Site Status

1245.36.85205 Boehringer Ingelheim Investigational Site

Hong Kong, , Hong Kong

Site Status

1245.36.85206 Boehringer Ingelheim Investigational Site

Hong Kong, , Hong Kong

Site Status

1245.36.85202 Boehringer Ingelheim Investigational Site

Kowloon, , Hong Kong

Site Status

1245.36.91209 Boehringer Ingelheim Investigational Site

Aligarh, Uttar Pradesh, , India

Site Status

1245.36.91202 Boehringer Ingelheim Investigational Site

Bangalore, , India

Site Status

1245.36.91204 Boehringer Ingelheim Investigational Site

Bangalore, , India

Site Status

1245.36.91205 Boehringer Ingelheim Investigational Site

Bangalore, , India

Site Status

1245.36.91208 Boehringer Ingelheim Investigational Site

Bangalore, , India

Site Status

1245.36.91201 Boehringer Ingelheim Investigational Site

Chennai, , India

Site Status

1245.36.91214 Boehringer Ingelheim Investigational Site

Chennai, , India

Site Status

1245.36.91213 Boehringer Ingelheim Investigational Site

Gurgaon, , India

Site Status

1245.36.91203 Boehringer Ingelheim Investigational Site

Hyderabad, , India

Site Status

1245.36.91211 Boehringer Ingelheim Investigational Site

Kolkata, , India

Site Status

1245.36.91210 Boehringer Ingelheim Investigational Site

Mangalore, , India

Site Status

1245.36.91215 Boehringer Ingelheim Investigational Site

Mumbai, Maharastra, , India

Site Status

1245.36.91216 Boehringer Ingelheim Investigational Site

Nashik, , India

Site Status

1245.36.91212 Boehringer Ingelheim Investigational Site

New Delhi, , India

Site Status

1245.36.91207 Boehringer Ingelheim Investigational Site

Pune, , India

Site Status

1245.36.60003 Boehringer Ingelheim Investigational Site

Johor Baru, , Malaysia

Site Status

1245.36.60006 Boehringer Ingelheim Investigational Site

Kelantan Kota Bahru, , Malaysia

Site Status

1245.36.60005 Boehringer Ingelheim Investigational Site

Kuala Lumpur, , Malaysia

Site Status

1245.36.60009 Boehringer Ingelheim Investigational Site

Kuala Lumpur, , Malaysia

Site Status

1245.36.60004 Boehringer Ingelheim Investigational Site

Kuala Pahang, , Malaysia

Site Status

1245.36.60007 Boehringer Ingelheim Investigational Site

Perak, , Malaysia

Site Status

1245.36.60011 Boehringer Ingelheim Investigational Site

Perak, , Malaysia

Site Status

1245.36.60010 Boehringer Ingelheim Investigational Site

Pulau Piang, , Malaysia

Site Status

1245.36.60008 Boehringer Ingelheim Investigational Site

Sabak Bernam, , Malaysia

Site Status

1245.36.60001 Boehringer Ingelheim Investigational Site

Selangor Darul Ehsan, , Malaysia

Site Status

1245.36.31015 Boehringer Ingelheim Investigational Site

Amersfoort, , Netherlands

Site Status

1245.36.31012 Boehringer Ingelheim Investigational Site

Geleen, , Netherlands

Site Status

1245.36.31017 Boehringer Ingelheim Investigational Site

Hardenberg, , Netherlands

Site Status

1245.36.31009 Boehringer Ingelheim Investigational Site

Maastricht, , Netherlands

Site Status

1245.36.31004 Boehringer Ingelheim Investigational Site

The Hague, , Netherlands

Site Status

1245.36.31002 Boehringer Ingelheim Investigational Site

Utrecht, , Netherlands

Site Status

1245.36.31003 Boehringer Ingelheim Investigational Site

Zaandam, , Netherlands

Site Status

1245.36.63008 Boehringer Ingelheim Investigational Site

Cavite City, , Philippines

Site Status

1245.36.63006 Boehringer Ingelheim Investigational Site

Cebu, , Philippines

Site Status

1245.36.63005 Boehringer Ingelheim Investigational Site

Manila, , Philippines

Site Status

1245.36.63007 Boehringer Ingelheim Investigational Site

Manila, , Philippines

Site Status

1245.36.63009 Boehringer Ingelheim Investigational Site

Marikina City, , Philippines

Site Status

1245.36.63010 Boehringer Ingelheim Investigational Site

Tacloban City, , Philippines

Site Status

1245.36.48006 Boehringer Ingelheim Investigational Site

Gdansk, , Poland

Site Status

1245.36.48003 Boehringer Ingelheim Investigational Site

Lodz, , Poland

Site Status

1245.36.48004 Boehringer Ingelheim Investigational Site

Lodz, , Poland

Site Status

1245.36.48001 Boehringer Ingelheim Investigational Site

Lublin, , Poland

Site Status

1245.36.48002 Boehringer Ingelheim Investigational Site

Poznan, , Poland

Site Status

1245.36.48007 Boehringer Ingelheim Investigational Site

Ruda Śląska, , Poland

Site Status

1245.36.48005 Boehringer Ingelheim Investigational Site

Torun, , Poland

Site Status

1245.36.35003 Boehringer Ingelheim Investigational Site

Faro, , Portugal

Site Status

1245.36.35002 Boehringer Ingelheim Investigational Site

Lisbon, , Portugal

Site Status

1245.36.35004 Boehringer Ingelheim Investigational Site

Lisbon, , Portugal

Site Status

1245.36.35001 Boehringer Ingelheim Investigational Site

Vila Nova de Gaia, , Portugal

Site Status

1245.36.70008 Boehringer Ingelheim Investigational Site

Moscow, , Russia

Site Status

1245.36.70009 Boehringer Ingelheim Investigational Site

Moscow, , Russia

Site Status

1245.36.70011 Boehringer Ingelheim Investigational Site

Moscow, , Russia

Site Status

1245.36.70004 Boehringer Ingelheim Investigational Site

Saint Petersburg, , Russia

Site Status

1245.36.70006 Boehringer Ingelheim Investigational Site

Saint Petersburg, , Russia

Site Status

1245.36.70002 Boehringer Ingelheim Investigational Site

Vsevolozhsk, , Russia

Site Status

1245.36.74011 Boehringer Ingelheim Investigational Site

Moldava nad Bodvou, , Slovakia

Site Status

1245.36.74013 Boehringer Ingelheim Investigational Site

Nitra, , Slovakia

Site Status

1245.36.74008 Boehringer Ingelheim Investigational Site

Nové Mesto nad Váhom, , Slovakia

Site Status

1245.36.74012 Boehringer Ingelheim Investigational Site

Prešov, , Slovakia

Site Status

1245.36.74007 Boehringer Ingelheim Investigational Site

Trenčín, , Slovakia

Site Status

1245.36.74009 Boehringer Ingelheim Investigational Site

Žilina, , Slovakia

Site Status

1245.36.76021 Boehringer Ingelheim Investigational Site

Plumstead, , South Africa

Site Status

1245.36.76020 Boehringer Ingelheim Investigational Site

Somerset West, , South Africa

Site Status

1245.36.76022 Boehringer Ingelheim Investigational Site

Somerset West, , South Africa

Site Status

1245.36.34015 Boehringer Ingelheim Investigational Site

Barcelona, , Spain

Site Status

1245.36.34009 Boehringer Ingelheim Investigational Site

Granada, , Spain

Site Status

1245.36.34014 Boehringer Ingelheim Investigational Site

L'Hospitalet de Llobregat, , Spain

Site Status

1245.36.34012 Boehringer Ingelheim Investigational Site

Madrid, , Spain

Site Status

1245.36.34013 Boehringer Ingelheim Investigational Site

Madrid, , Spain

Site Status

1245.36.34020 Boehringer Ingelheim Investigational Site

Manresa, , Spain

Site Status

1245.36.34021 Boehringer Ingelheim Investigational Site

San Sebastián de los Reyes, , Spain

Site Status

1245.36.34016 Boehringer Ingelheim Investigational Site

Santiago de Compostela, , Spain

Site Status

1245.36.34017 Boehringer Ingelheim Investigational Site

Valencia, , Spain

Site Status

1245.36.34019 Boehringer Ingelheim Investigational Site

Valencia, , Spain

Site Status

1245.36.44018 Boehringer Ingelheim Investigational Site

Bath, , United Kingdom

Site Status

1245.36.44010 Boehringer Ingelheim Investigational Site

Birmingham, , United Kingdom

Site Status

1245.36.44013 Boehringer Ingelheim Investigational Site

Blackpool, , United Kingdom

Site Status

1245.36.44016 Boehringer Ingelheim Investigational Site

Blackpool, , United Kingdom

Site Status

1245.36.44026 Boehringer Ingelheim Investigational Site

Chester, , United Kingdom

Site Status

1245.36.44012 Boehringer Ingelheim Investigational Site

Chesterfield, , United Kingdom

Site Status

1245.36.44025 Boehringer Ingelheim Investigational Site

Doncaster, , United Kingdom

Site Status

1245.36.44036 Boehringer Ingelheim Investigational Site

Epsom, , United Kingdom

Site Status

1245.36.44001 Boehringer Ingelheim Investigational Site

Frome, , United Kingdom

Site Status

1245.36.44007 Boehringer Ingelheim Investigational Site

Midsomer Norton, , United Kingdom

Site Status

1245.36.44023 Boehringer Ingelheim Investigational Site

Nantwich, , United Kingdom

Site Status

1245.36.44024 Boehringer Ingelheim Investigational Site

Welwyn Garden City, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada France Hong Kong India Malaysia Netherlands Philippines Poland Portugal Russia Slovakia South Africa Spain United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Natale P, Tunnicliffe DJ, Toyama T, Palmer SC, Saglimbene VM, Ruospo M, Gargano L, Stallone G, Gesualdo L, Strippoli GF. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes. Cochrane Database Syst Rev. 2024 May 21;5(5):CD015588. doi: 10.1002/14651858.CD015588.pub2.

Reference Type DERIVED
PMID: 38770818 (View on PubMed)

Tuttle KR, Levin A, Nangaku M, Kadowaki T, Agarwal R, Hauske SJ, Elsasser A, Ritter I, Steubl D, Wanner C, Wheeler DC. Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials. Diabetes Care. 2022 Jun 2;45(6):1445-1452. doi: 10.2337/dc21-2034.

Reference Type DERIVED
PMID: 35472672 (View on PubMed)

Cherney D, Lund SS, Perkins BA, Groop PH, Cooper ME, Kaspers S, Pfarr E, Woerle HJ, von Eynatten M. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia. 2016 Sep;59(9):1860-70. doi: 10.1007/s00125-016-4008-2. Epub 2016 Jun 17.

Reference Type DERIVED
PMID: 27316632 (View on PubMed)

Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, Broedl UC; EMPA-REG RENAL trial investigators. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014 May;2(5):369-84. doi: 10.1016/S2213-8587(13)70208-0. Epub 2014 Jan 24.

Reference Type DERIVED
PMID: 24795251 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2009-016179-31

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

1245.36

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Renal Impairment in Type 2 Diabetic Subjects
NCT00554450 COMPLETED PHASE1
A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease
NCT05182840 COMPLETED PHASE2
Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease
NCT05465317 COMPLETED
Safety and Efficacy of Empagliflozin (BI 10773) in Type 1 Diabetes Mellitus Patients With or Without Renal Hyperfiltration
NCT01392560 COMPLETED PHASE2
This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated
NCT03165240 COMPLETED PHASE1
Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment
NCT00663260 COMPLETED PHASE2/PHASE3
Study of LY3016859 in Participants With Diabetic Nephropathy
NCT01774981 COMPLETED PHASE1/PHASE2
A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes
NCT05254002 COMPLETED PHASE2
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BI 10773 in Type II Diabetes Patients With Different Degrees of Renal Impairment
NCT01907113 COMPLETED PHASE1
Bioequivalence Study of Empagliflozin Tablet in Healthy Participants.
NCT03771781 COMPLETED NA
Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease
NCT07271186 NOT_YET_RECRUITING PHASE2
A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes
NCT02413398 COMPLETED PHASE3
Effects of Dapagliflozin on Kidney Function (Glomerular Filtration Rate) in Subjects With Type 2 Diabetes
NCT00976495 COMPLETED PHASE2
An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
NCT01064414 COMPLETED PHASE3
A Phase 2b Diabetic Kidney Disease Study
NCT04170543 COMPLETED PHASE2
A Study in Participants With Diabetic Kidney Disease
NCT01113801 TERMINATED PHASE2
A Comparison of Effectiveness, Safety, and Cost-effectiveness of Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes Mellitus and High Body Mass Index (BMI)
NCT07311551 NOT_YET_RECRUITING PHASE4
Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes
NCT03132181 COMPLETED PHASE2
Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors
NCT02864914 COMPLETED
A Bioequivalence Study of Two Formulations of 10-mg Empagliflozin Tablets in Healthy Thai Volunteers Under Fasting Conditions
NCT06308679 NOT_YET_RECRUITING PHASE1
Empa PASS on Urinary Tract Malignancies
NCT03464045 COMPLETED
A Study of LY2928057 in Hemodialysis Participants
NCT01991483 COMPLETED PHASE1
Impact of the SGLT2 Inhibitor Empagliflozin on Urinary Supersaturations in Kidney Stone Formers
NCT04911660 COMPLETED PHASE2
Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD
NCT06110130 RECRUITING PHASE4
Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial
NCT06094920 ENROLLING_BY_INVITATION PHASE4